2025/08/26 更新

写真a

イシダ ジョウジ
石田 穣治
ISHIDA Jouji
所属
医歯薬学域 講師
職名
講師
外部リンク

学位

  • 博士(医学) ( 岡山大学 )

 

論文

  • Identification of factors related to functional prognoses in craniopharyngiomas. 国際誌

    Tsuyoshi Umeda, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Shuichiro Hirano, Yasuki Suruga, Naoya Kemmotsu, Ryoji Imoto, Yasuhito Kegoya, Ryo Mizuta, Yohei Inoue, Madoka Hokama, Seiichiro Makihara, Kosei Hasegawa, Kenichi Inagaki, Fumio Otsuka, Takao Yasuhara, Shota Tanaka

    Journal of neuro-oncology   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Craniopharyngiomas are histologically benign tumors, but their proximity to vital neurovascular structures can significantly deteriorate functional prognoses and severely restrict patients' social interaction and activity. We retrospectively identified risk factors related to the functional prognoses in patients with craniopharyngioma treated at our center. METHODS: A retrospective analysis was conducted on 40 patients who underwent surgery for craniopharyngioma and follow-up at our institution between 2003 and 2022. Functional prognoses were evaluated in terms of obesity (body mass index [BMI] ≥ 25 for adults, BMI-Z ≥ 1.65 for children), visual function, endocrine function, and social participation. We investigated whether patient characteristics, tumor size, tumor location, hypothalamic involvement, surgical hypothalamic damage, extent of resection, and recurrence rate correlated with these functional prognostic factors. RESULTS: The median age at diagnosis was 28.0 years, with a median follow-up of 80.5 months. Postoperative obesity was present in 22 patients, and those with postoperative obesity had a significantly higher preoperative BMI or BMI-Z (preoperative BMI for adults: p = 0.074; preoperative BMI-Z for children: p = 0.020) and were significantly correlated with preoperative hypothalamic involvement grade 2 (p = 0.012) and surgical hypothalamic damage grade II (p = 0.0001). Deterioration in social participation was significantly associated with a larger tumor size (p = 0.023) and tumor recurrence (p = 0.0047). CONCLUSIONS: Patients with higher preoperative BMI or BMI-Z and hypothalamic involvement have a greater risk of postoperative obesity, and larger tumor size and recurrence can significantly deteriorate the rate of patients' social participation.

    DOI: 10.1007/s11060-024-04925-7

    PubMed

    researchmap

  • Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy. 国際誌

    Toshifumi Ninomiya, Naoya Kemmotsu, Fumiaki Mukohara, Masaki Magari, Ai Miyamoto, Youki Ueda, Takamasa Ishino, Joji Nagasaki, Tomohiro Fujiwara, Hidetaka Yamamoto, Hidetoshi Hayashi, Kota Tachibana, Joji Ishida, Yoshihiro Otani, Shota Tanaka, Shinichi Toyooka, Isamu Okamoto, Yosuke Togashi

    Cancer research   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Brain metastasis (BM) is a poor prognostic factor in cancer patients. Despite showing efficacy in many extracranial tumors, immunotherapy with anti-PD-1 monoclonal antibody (mAb) or anti-CTLA-4 mAb appears to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti-PD-1 and anti-CTLA-4 mAbs has a potent antitumor effect on BM, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies. Here, we analyzed the tumor-infiltrating lymphocytes in murine models of BM that responded to anti-CTLA-4 mAb to anti-PD-1 mAb. Activated CD4+ T follicular helper (TFH) cells with high CTLA-4 expression characteristically infiltrated the intracranial TME, which were activated by the combination anti-CTLA-4 and anti-PD-1 treatment. Loss of TFH cells suppressed the additive effect of CTLA-4 blockade on anti-PD-1 mAb. B cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) produced by abundant myeloid cells, particularly CD80hiCD206lo pro-inflammatory M1-like macrophages, in the intracranial TME, induced B cell and TFH cell infiltration and activation. Furthermore, the intracranial TME of patients with non-small cell lung cancer featured TFH and B cell infiltration as tertiary lymphoid structures. Together, these findings provide insights into the immune cell crosstalk in the intracranial TME that facilitates an additive anti-tumor effect of CTLA-4 blockade with anti-PD-1 treatment, supporting the potential of a combination immunotherapeutic strategy for BM.

    DOI: 10.1158/0008-5472.CAN-24-2274

    PubMed

    researchmap

  • Comparative analysis of intraoperative MRI and early postoperative MRI findings in glioma surgery patients. 国際誌

    Yoshihiro Otani, Fumiyo Higaki, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Shuichiro Hirano, Naoya Kemmotsu, Yasuki Suruga, Ryoji Imoto, Ryo Mizuta, Yasuhito Kegoya, Yohei Inoue, Tsuyoshi Umeda, Madoka Hokama, Takao Yasuhara, Takao Hiraki, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Shota Tanaka, Isao Date

    Journal of neurosurgery   1 - 9   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: The extent of resection (EOR) is an important prognostic factor for both low- and high-grade gliomas. Intraoperative MRI (iMRI) has been used to increase the EOR in glioma surgery. While a recent study reported differences between iMRI and early postoperative MRI (epMRI), their specific relationship to postoperative clinical symptoms remains unclear. This study aims to compare the differences between iMRI and epMRI in glioma surgery. METHODS: A retrospective assessment was conducted on 43 patients with glioma who underwent surgery with iMRI and for whom no additional resection was performed after iMRI. The study evaluated the discrepancies in EOR, surgically induced contrast enhancement (SICE), and diffusion-weighted imaging (DWI) abnormality between iMRI and epMRI. EOR was defined as gross-total resection (GTR), near-total resection, subtotal resection (STR), or partial resection (PR) for enhancing lesions, and GTR, STR, or PR for nonenhancing lesions. In addition, the relationship between postoperative neurological findings and iMRI findings was evaluated. RESULTS: Discrepancies in EOR were observed in 2 (11.1%) of 18 cases with nonenhanced lesions and 1 (4.0%) of 25 cases with enhanced lesions. The positive rate of SICE was 25.0% on iMRI and 67.9% on epMRI. Enhancement at the resection cavity was the most frequent pattern in both iMRI and epMRI. The positive rate of enhancement of the resection cavity was strongly increased on epMRI compared with iMRI, potentially mimicking residual tumor. The positive rate of DWI abnormality was 73% on iMRI and 89.2% on epMRI. Among the 10 patients who showed no DWI abnormality on iMRI, 6 exhibited DWI abnormality on epMRI (the late-developing group). Two patients developed new neurological deficits postoperatively, and both showed DWI abnormality on both iMRI and epMRI. No patient in the late-developing group developed postoperative neurological deficits. CONCLUSIONS: Overall, iMRI demonstrated more accurate EOR and less SICE compared with epMRI. Although the positive rate of DWI abnormality was lower on iMRI than on epMRI, the late-developing group showed no postoperative neurological deficits. Therefore, iMRI is more useful in assessing accurate EOR and detecting postoperative neurological deficits than epMRI.

    DOI: 10.3171/2024.7.JNS24784

    PubMed

    researchmap

  • EXTH-04. COMBINATION OF BEVACIZUMAB ENHANCES THE ANTI-TUMOR EFFICACY OF AD-SGE-REIC FOR GLIOMA

    Yoshihiro Otani, Yasuhiko Hattori, Atsuhito Uneda, Nobushige Tsuboi, Keigo Makino, Shuichiro Hirano, Joji Ishida, Kentaro Fujii, Yusuke Tomita, Tetsuo Oka, Yuji Matsumoto, Yosuke Shimazu, Hiroyuki Michiue, Kazuhiko Kurozumi, Hiromu Kumon, Isao Date, Shota Tanaka

    Neuro-Oncology   26 ( Supplement_8 )   viii236 - viii237   2024年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    Abstract

    Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) is a tumor suppressor gene and its overexpression has been shown to exert anti-tumor effects as a therapeutic target gene in many human cancers. Recently, we revealed the anti-glioma effects of an adenoviral vector carrying REIC/Dkk-3 with the super gene expression system (Ad-SGE-REIC) and conducted the phase Ⅰ/Ⅱ a clinical trial for recurrent malignant glioma (jRCT2063190013). Anti-vascular endothelial growth factor treatments such as bevacizumab have demonstrated convincing therapeutic efficacy in patients with glioma. In this study, we examined the effects of Ad-SGE-REIC on glioma treated with bevacizumab in vitro and in vivo. Ad-SGE-REIC treatment resulted in a significant reduction in the number of invasion cells treated with bevacizumab. Western blot analyses revealed the increased expression of several endoplasmic reticulum stress markers in cells treated with both bevacizumab and Ad-SGE-REIC, as well as decreased β-catenin protein levels. In glioma-bearing mouse models, survival was extended in the combination therapy group. These results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab showed anti-glioma effects by suppressing the angiogenesis and invasion of tumor cells. Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma.

    DOI: 10.1093/neuonc/noae165.0935

    researchmap

  • TMIC-31. MOLECULAR PROGNOSTIC FACTORS OF THE PROGRESSION OF VESTIBULAR SCHWANNOMA AFTER PRIMARY TUMOR RESECTION

    Ryo Mizuta, Keigo Makino, Yoshihiro Otai, Kentaro Fujii, Joji Ishida, Atsuhito Uneda, Nobushige Tsuboi, Shuichiro Hirano, Naoya Kemmotsu, Yasuki Suruga, Ryoji Imoto, Yasuhito Kegoya, Madoka Hokama, Ryosuke Ikemachi, Yuji Matsumoto, Yusuke Tomita, Yosuke Shimazu, Hirofumi Inoue, Yuanqing Yan, Ziyi Wang, Mitsuaki Ono, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Takao Yasuhara, Shota Tanaka

    Neuro-Oncology   26 ( Supplement_8 )   viii304 - viii305   2024年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    Abstract

    BACKGROUND

    Although vestibular schwannoma is a benign tumor, 10% of the tumor regrow after primary tumor resection. The factors associated with tumor progression from several reports remain controversial, and the role of the tumor microenvironment in vestibular schwannoma is still unclear. In this study, we analyzed the prognostic factors associated with the tumor progression after primary resection.

    METHODS

    We retrospectively reviewed the medical records of patients who underwent surgical resection and were diagnosed with vestibular schwannoma between January 2005 and June 2020. We performed RNA sequencing to identify the prognostic factors and immunohistochemistry to assess the tumor microenvironment, including analysis of the CD80 and CD206 expression of macrophages. We compared the progressed group whose tumor size got larger than 2mm after primary resection or who underwent additional treatment because of regrowth with the stable group.

    RESULTS

    Fifty-five patients underwent surgical resection for newly diagnosed vestibular schwannoma, and 12 of them had tumor regrowth. RNA sequencing revealed that the significantly upregulated pathways in the stable group was related to immune systems, while that of the progressed group was related to cell cycle. In addition, there were more myeloid cells, especially M2 macrophage infiltration in the stable group. Immunohistochemistry also showed higher M2 macrophages in the stable group.

    CONCLUSION

    In this study, multiomic analysis revealed the upregulation of immune-related pathways in the stable group and the cell cycle pathway in the progressed group. Altering the tumor microenvironment may offer a therapeutic strategy in vestibular schwannoma after primary resection.

    DOI: 10.1093/neuonc/noae165.1209

    researchmap

  • Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis.

    Ryoji Imoto, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Shuichiro Hirano, Naoya Kemmotsu, Yasuki Suruga, Ryo Mizuta, Yasuhito Kegoya, Yohei Inoue, Tsuyoshi Umeda, Madoka Hokama, Kana Washio, Hiroyuki Yanai, Shota Tanaka, Kaishi Satomi, Koichi Ichimura, Isao Date

    Brain tumor pathology   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Tectal glioma (TG) is a rare lower grade glioma (LrGG) that occurs in the tectum, mainly affecting children. TG shares pathological similarities with pilocytic astrocytoma (PA), but recent genetic analyses have revealed distinct features, such as alterations in KRAS and BRAF. We conducted a retrospective review of cases clinically diagnosed as TG and treated at our institute between January 2005 and March 2023. Six cases were identified and the median age was 30.5 years. Four patients underwent biopsy and two patients underwent tumor resection. Histological diagnoses included three cases of PA, one case of astrocytoma, and two cases of high-grade glioma. The integrated diagnosis, according to the fifth edition of the World Health Organization Classification of Tumours of the central nervous system, included two cases of PA and one case each of diffuse high-grade glioma; diffuse midline glioma H3 K27-altered; glioblastoma; and circumscribed astrocytic glioma. Among the three patients who underwent molecular evaluation, two had KRAS mutation and one had H3-3A K27M mutation. Our results demonstrate the diverse histological and molecular characteristics of TG distinct from other LrGGs. Given the heterogeneous pathological background and the risk of pathological progression in TG, we emphasize the importance of comprehensive diagnosis, including molecular evaluation.

    DOI: 10.1007/s10014-024-00494-9

    PubMed

    researchmap

  • New Anti-Angiogenic Therapy for Glioblastoma With the Anti-Depressant Sertraline. 国際誌

    Nobushige Tsuboi, Yoshihiro Otani, Atsuhito Uneda, Joji Ishida, Yasuki Suruga, Yuji Matsumoto, Atsushi Fujimura, Kentaro Fujii, Hideki Matsui, Kazuhiko Kurozumi, Isao Date, Hiroyuki Michiue

    Cancer medicine   13 ( 20 )   e70288   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Anti-angiogenic therapies prolong patient survival in some malignancies but not glioblastoma. We focused on the relationship between the differentiation of glioma stem like cells (GSCs) into tumor derived endothelial cells (TDECs) and, anti-angiogenic therapy resistance. Especially we aimed to elucidate the mechanisms of drug resistance of TDECs to anti-angiogenic inhibitors and identify novel anti-angiogenic drugs with clinical applications. RESULTS: The mouse GSCs, 005, were differentiated into TDECs under hypoxic conditions, and TDECs had endothelial cell characteristics independent of the vascular endothelial growth factor (VEGF) pathway. In vivo, inhibition of the VEGF pathway had no anti-tumor effect and increased the percentage of TDECs in the 005 mouse model. Novel anti-angiogenic drugs for glioblastoma were evaluated using a tube formation assay and a drug repositioning strategy with existing blood-brain barrier permeable drugs. Drug screening revealed that the antidepressant sertraline inhibited tube formation of TDECs. Sertraline was administered to differentiated TDECs in vitro and 005 mouse models in vivo to evaluate genetic changes by RNA-Seq and tumor regression effects by immunohistochemistry and MRI. Sertraline reduced Lama4 and Ang2 expressions of TDEC, which play an important role in non-VEGF-mediated angiogenesis in tumors. The combination of a VEGF receptor inhibitor axitinib, and sertraline improved survival and reduced tumor growth in the 005 mouse model. CONCLUSION: Collectively, our findings showed the diversity of tumor vascular endothelial cells across VEGF and non-VEGF pathways led to anti-angiogenic resistance. The combination of axitinib and sertraline can represent an effective anti-angiogenic therapy for glioblastoma with safe, low cost, and fast availability.

    DOI: 10.1002/cam4.70288

    PubMed

    researchmap

  • 中枢神経原発リンパ腫におけるplasmablastサブポピュレーションの分子学的特性について

    小林 宏紀, 千々松 良太, 直井 友亮, 大谷 理浩, 水田 亮, 藤井 謙太郎, 石田 穣治, 村上 裕之, 氏家 英貴, 池内 一廣, 浦田 知宏, 清家 圭介, 藤原 英晃, 淺田 騰, 藤井 伸治, 松岡 賢市, 佐藤 康晴, 前田 嘉信, 遠西 大輔

    日本血液学会学術集会   86回   O3 - 2   2024年10月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本血液学会  

    researchmap

  • 脳腫瘍に対する全ゲノム解析(Whole-genome sequencing analysis of brain tumors)

    鈴木 啓道, 中島 拓真, 舟越 勇介, 金森 政之, 柴原 一陽, 鈴木 智成, 木下 学, 園田 順彦, 荒川 芳輝, 永根 基雄, 田中 將太, 石田 穣治, 齋藤 竜太, 花谷 亮典, 吉本 幸司, 成田 善孝

    日本癌学会総会記事   83回   S08 - 3   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 脳腫瘍の分子診断と治療2 NF1関連グリオーマにおける腫瘍微小環境の解析

    駿河 和城, 大谷 理浩, 松本 悠司, 平野 秀一郎, 藤井 謙太郎, 石田 穣治, 柳井 広之, 田中 將太

    Brain Tumor Pathology   41 ( Suppl. )   100 - 100   2024年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 【頭蓋頸椎移行部病変】Chiari奇形に対する治療

    安原 隆雄, 佐々田 晋, 石田 穣治, 金 恭平

    脊椎脊髄ジャーナル   37 ( 4 )   267 - 273   2024年5月

  • 当院で経験したDiffuse midline glioma,H3K27-alteredの臨床的特徴

    外間 まどか, 大谷 理浩, 石田 穣治, 梅田 剛志, 井上 陽平, 水田 亮, 井本 良二, 駿河 和城, 劒持 直也, 家護谷 泰仁, 平野 秀一郎, 冨田 祐介, 藤井 謙太郎, 鷲尾 佳奈, 田中 將太

    小児の脳神経   49 ( 2 )   209 - 209   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 頭蓋咽頭腫の神経内分泌機能予後に関する因子の検討

    梅田 剛志, 大谷 理浩, 井上 陽平, 外間 まどか, 水田 亮, 井本 良二, 駿河 和城, 劒持 直也, 家護谷 泰仁, 平野 秀一郎, 石田 穣治, 藤井 謙太郎, 安原 隆雄, 長谷川 高誠, 稲垣 兼一, 伊達 勲

    日本内分泌学会雑誌   99 ( 5 )   1422 - 1422   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内分泌学会  

    researchmap

  • 当院で経験したDiffuse midline glioma,H3K27-alteredの臨床的特徴

    外間 まどか, 大谷 理浩, 石田 穣治, 梅田 剛志, 井上 陽平, 水田 亮, 井本 良二, 駿河 和城, 劒持 直也, 家護谷 泰仁, 平野 秀一郎, 冨田 祐介, 藤井 謙太郎, 鷲尾 佳奈, 田中 將太

    小児の脳神経   49 ( 2 )   209 - 209   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • Combined simultaneous endoscopic endonasal and transcranial surgery using high-definition three-dimensional exoscope for malignant tumors of the anterior skull base. 査読 国際誌

    Seiichiro Makihara, Yoshihiro Otani, Kensuke Uraguchi, Aiko Shimizu, Aya Murai, Takaya Higaki, Naoki Akisada, Shohei Fujimoto, Takuma Makino, Joji Ishida, Kentaro Fujii, Takao Yasuhara, Tomoyuki Ota, Hiroshi Matsumoto, Mizuo Ando

    Head & neck   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Advanced surgical interventions are required to treat malignancies in the anterior skull base (ASB). This study investigates the utility of endoscopic endonasal and transcranial surgery (EETS) using a high-definition three-dimensional exoscope as an alternative to traditional microscopy. METHODS: Six patients with carcinomas of varying histopathologies underwent surgery employing the EETS maneuver, which synchronized three distinct surgical modalities: harvesting of the anterolateral thigh flap, initiation of the transnasal technique, and initiation of the transcranial procedure. RESULTS: The innovative strategy enabled successful tumor resection and skull base reconstruction without postoperative local neoplastic recurrence, cerebrospinal fluid leakage, or neurological deficits. CONCLUSION: The integration of the exoscope and EETS is a novel therapeutic approach for ASB malignancies. This strategy demonstrates the potential of the exoscope in augmenting surgical visualization, enhancing ergonomics, and achieving seamless alignment of multiple surgical interventions. This technique represents a progressive shift in the management of these complex oncological challenges.

    DOI: 10.1002/hed.27724

    PubMed

    researchmap

  • Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review. 査読 国際誌

    Yasuhito Kegoya, Yoshihiro Otani, Yohei Inoue, Ryo Mizuta, Fumiyo Higaki, Kana Washio, Shinichiro Koizumi, Kazuhiko Kurozumi, Joji Ishida, Kentaro Fujii, Norio Yamamoto, Yoshihiro Tanaka, Isao Date

    Journal of neuro-oncology   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Diffuse hemispheric glioma, H3 G34-mutant (DHGs), is a newly categorized tumor in pediatric-type diffuse high-grade gliomas, World Health Organization grade 4, with a poor prognosis. Although prognostic factors associated with genetic abnormalities have been reported, few reports have examined the clinical presentation of DHGs, especially from the viewpoint of imaging findings. In this study, we investigated the relationship between clinical factors, including imaging findings, and prognosis in patients with DHGs. METHODS: We searched Medline through the PubMed database using two search terms: "G34" and "glioma", between 1 April 2012 and 1 July 2023. We retrieved articles that described imaging findings and overall survival (OS), and added one DHG case from our institution. We defined midline invasion (MI) as invasion to the contralateral cerebrum, brainstem, corpus callosum, thalamus, and basal ganglia on magnetic resonance imaging. The primary outcome was 12-month survival, estimated using Kaplan-Meier curves and logistic regression. RESULTS: A total of 96 patients were included in this study. The median age was 22 years, and the proportion of male patients was 48.4%. Lesions were most frequently located in the frontal lobe (52.6%). MI was positive in 39.6% of all patients. The median OS was 14.4 months. Univariate logistic regression analysis revealed that OS was significantly worse in the MI-positive group compared with the MI-negative group. Multivariate logistic regression analysis revealed that MI was an independent prognostic factor in DHGs. CONCLUSIONS: In this study, MI-positive cases had a worse prognosis compared with MI-negative cases. PREVIOUS PRESENTATIONS: No portion of this study has been presented or published previously.

    DOI: 10.1007/s11060-024-04587-5

    PubMed

    researchmap

  • Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study. 査読 国際誌

    Kohei Fukuoka, Jun Kurihara, Tomoko Shofuda, Naoki Kagawa, Kai Yamasaki, Ryo Ando, Joji Ishida, Masayuki Kanamori, Atsufumi Kawamura, Young-Soo Park, Chikako Kiyotani, Takuya Akai, Dai Keino, Yosuke Miyairi, Atsushi Sasaki, Junko Hirato, Takeshi Inoue, Atsuko Nakazawa, Katsuyoshi Koh, Ryo Nishikawa, Isao Date, Motoo Nagane, Koichi Ichimura, Yonehiro Kanemura

    Acta neuropathologica communications   11 ( 1 )   153 - 153   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: One of the most significant challenges in patients with medulloblastoma is reducing the dose of craniospinal irradiation (CSI) to minimize neurological sequelae in survivors. Molecular characterization of patients receiving lower than standard dose of CSI therapy is important to facilitate further reduction of treatment burden. METHODS: We conducted DNA methylation analysis using an Illumina Methylation EPIC array to investigate molecular prognostic markers in 38 patients with medulloblastoma who were registered in the Japan Pediatric Molecular Neuro-Oncology Group and treated with reduced-dose CSI. RESULTS: Among the patients, 23 were classified as having a standard-risk and 15 as high-risk according to the classic classification based on tumor resection rate and presence of metastasis, respectively. The median follow-up period was 71.5 months (12.0-231.0). The median CSI dose was 18 Gy (15.0-24.0) in both groups, and 5 patients in the high-risk group received a CSI dose of 18.0 Gy. Molecular subgrouping revealed that the standard-risk cohort included 5 WNT, 2 SHH, and 16 Group 3/4 cases; all 15 patients in the high-risk cohort had Group 3/4 medulloblastoma. Among the patients with Group 3/4 medulloblastoma, 9 of the 31 Group 3/4 cases were subclassified as subclass II, III, and V, which were known to an association with poor prognosis according to the novel subtyping among the subgroups. Patients with poor prognostic subtype showed worse prognosis than that of others (5-year progression survival rate 90.4% vs. 22.2%; p < 0.0001). The result was replicated in the multivariate analysis (hazard ratio12.77, 95% confidence interval for hazard ratio 2.38-99.21, p value 0.0026 for progression-free survival, hazard ratio 5.02, 95% confidence interval for hazard ratio 1.03-29.11, p value 0.044 for overall survival). CONCLUSION: Although these findings require validation in a larger cohort, the present findings suggest that novel subtyping of Group 3/4 medulloblastoma may be a promising prognostic biomarker even among patients treated with lower-dose CSI than standard treatment.

    DOI: 10.1186/s40478-023-01652-4

    PubMed

    researchmap

  • Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.

    Keigo Makino, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Shuichiro Hirano, Yasuki Suruga, Kana Washio, Kenji Nishida, Hiroyuki Yanai, Shuta Tomida, Daisuke Ennishi, Isao Date

    Acta medica Okayama   77 ( 3 )   323 - 330   2023年6月

     詳細を見る

    記述言語:英語  

    In the current World Health Organization classification of central nervous system tumors, comprehensive genetic and epigenetic analyses are considered essential for precise diagnosis. A 14-year-old male patient who presented with a cerebellar tumor was initially diagnosed with glioblastoma and treated with radiation and concomitant temozolomide chemotherapy after resection. During maintenance temozolomide therapy, a new contrast-enhanced lesion developed in the bottom of the cavity formed by the resection. A second surgery was performed, but the histological findings in specimens from the second surgery were different from those of the first surgery. Although genome-wide DNA methylation profiling was conducted using frozen tissue for a precise diagnosis, the proportion of tumor cells was insufficient and only normal cerebellum was observed. We then performed comprehensive genetic analysis using formalin-fixed paraffin-embedded sections, which revealed MYCN amplification without alteration of IDH1, IDH2, or Histone H3. Finally, the patient was diagnosed with pediatric-type diffuse high-grade glioma, H3-wildtype and IDH-wildtype. In conclusion, comprehensive genetic and epigenetic analysis should be considered in pediatric brain tumor cases.

    DOI: 10.18926/AMO/65502

    PubMed

    researchmap

  • 脳腫瘍のメチル化診断 診断困難症例に対するゲノムワイドメチル化解析の検討

    大谷 理浩, 藤井 謙太郎, 石田 穣治, 駿河 和城, 鷲尾 佳奈, 柳井 広之, 里見 介史, 市村 幸一, 伊達 勲

    Brain Tumor Pathology   40 ( Suppl. )   062 - 062   2023年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.

    Yoshihiro Otani, Kaishi Satomi, Yasuki Suruga, Joji Ishida, Kentaro Fujii, Koichi Ichimura, Isao Date

    Brain tumor pathology   40 ( 2 )   56 - 65   2023年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient's outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in the clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed.

    DOI: 10.1007/s10014-023-00457-6

    PubMed

    researchmap

  • がんゲノム医療がもたらす小児脳腫瘍の展開 当院における小児グリオーマ診療について がんゲノム医療時代における変遷

    石田 穣治, 大谷 理浩, 藤井 謙太郎, 佐々木 達也, 鷲尾 佳奈, 柳井 広之, 遠西 大輔, 山本 英喜, 伊達 勲

    小児の脳神経   48 ( 2 )   153 - 153   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report.

    Takayuki Nagase, Joji Ishida, Susumu Sasada, Tatsuya Sasaki, Yoshihiro Otani, Satoru Yabuno, Kentaro Fujii, Atsuhito Uneda, Takao Yasuhara, Isao Date

    NMC case report journal   10   75 - 80   2023年

     詳細を見る

    記述言語:英語  

    Diffusely infiltrative midline gliomas are known to have a poor prognosis. The standard treatment for typical diffuse midline glioma in the pons is local radiotherapy as surgical resection is inappropriate. This case reports a brainstem glioma in which stereotactic biopsy and foramen magnum decompression were concomitantly performed to confirm the diagnosis and improve symptoms. A 23-year-old woman was referred to our department with a chief complaint of headache for six months. Magnetic resonance imaging (MRI) showed diffuse T2 hyperintense swelling of the brainstem with the pons as the main locus. Enlargement of the lateral ventricles was observed because of cerebrospinal fluid obstruction out of the posterior fossa. This was atypical for a diffuse midline glioma in terms of the longstanding slow progression of symptoms and patient age. Stereotactic biopsy was performed for diagnosis, and foramen magnum decompression (FMD) was concomitantly performed to treat the obstructive hydrocephalus. The histological diagnosis was astrocytoma, IDH-mutant. Post-surgery, the patient's symptoms were relieved, and she was discharged on the fifth day after surgery. The hydrocephalus was resolved, and the patient returned to normal life without any symptoms. The tumor size follow-up with MRI demonstrated no marked change for 12 months. Even though diffuse midline glioma is considered to have a poor prognosis, clinicians should contemplate if it is atypical. In atypical cases like the one described herein, surgical treatment may contribute to pathological diagnosis and symptom improvement.

    DOI: 10.2176/jns-nmc.2022-0159

    PubMed

    researchmap

  • [Surgical Tips and Precautions for Supratentorial Tumors in Children].

    Joji Ishida, Isao Date

    No shinkei geka. Neurological surgery   50 ( 6 )   1314 - 1322   2022年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Pediatric brain tumors account for approximately 15% of all pediatric cancers. Approximately half of the cases are malignant, and entail postoperative radiation therapy and chemotherapy. Herein, we describe perioperative tips and precautions for pediatric supratentorial tumors other than suprasellar tumors from our institution. Postoperative cerebrospinal fluid issues are especially prevalent in children, and three representative cases have been presented for discussion. Further, skull closure deems close attention, being crucial for children's future growth, in terms of a cosmetic aspect.

    DOI: 10.11477/mf.1436204697

    PubMed

    researchmap

  • The utility of DNA methylation analysis in elderly patients with pilocytic astrocytoma morphology. 国際誌

    Yasuki Suruga, Kaishi Satomi, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Atsuhito Uneda, Nobushige Tsuboi, Keigo Makino, Shuichiro Hirano, Naoya Kemmotsu, Ryoji Imoto, Ryo Mizuta, Yusuke Tomita, Takao Yasuhara, Kana Washio, Hiroyuki Yanai, Yuko Matsushita, Yuko Hibiya, Akihiko Yoshida, David Capper, Koichi Ichimura, Isao Date

    Journal of neuro-oncology   160 ( 1 )   179 - 189   2022年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s11060-022-04131-3

    Scopus

    PubMed

    researchmap

  • Age is a major determinant for poor prognosis in patients with pilocytic astrocytoma: a SEER population study. 国際誌

    Yusuke Tomita, Elizabeth A Hibler, Yasuki Suruga, Joji Ishida, Kentaro Fujii, Kaishi Satomi, Koichi Ichimura, Nobuyuki Hirotsune, Isao Date, Yoshihiro Tanaka, Yoshihiro Otani

    Clinical and experimental medicine   2022年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10238-022-00882-5

    Scopus

    PubMed

    researchmap

  • Genomic Profiling of a Case of Glioneuronal Tumor with Neuropil-like Islands.

    Nobushige Tsuboi, Joji Ishida, Yosuke Shimazu, Hisanori Edaki, Atsuhito Uneda, Yoshihiro Otani, Kentaro Fujii, Kazuhiko Kurozumi, Daisuke Ennishi, Hiroyuki Yanai, Isao Date

    Acta medica Okayama   76 ( 4 )   473 - 477   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18926/AMO/63907

    Scopus

    PubMed

    researchmap

  • 当院における毛様細胞性星細胞腫の予後因子に関する検討

    駿河 和城, 里見 介史, 大谷 理浩, 石田 穣治, 藤井 謙太郎, 安原 隆雄, 鷲尾 佳奈, 柳井 広之, 市村 幸一, 伊達 勲

    Brain Tumor Pathology   39 ( Suppl. )   103 - 103   2022年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • AYA世代の脳腫瘍病理 小児、AYA世代の脳腫瘍に対する網羅的メチル化解析を用いた診断の有用性と限界

    大谷 理浩, 藤井 謙太郎, 石田 穣治, 坪井 伸成, 鷲尾 佳奈, 柳井 広之, 里見 介史, 市村 幸一, 伊達 勲

    Brain Tumor Pathology   39 ( Suppl. )   076 - 076   2022年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy.

    Ryo Mizuta, Yoshihiro Otani, Kentaro Fujii, Atsuhito Uneda, Joji Ishida, Takehiro Tanaka, Shuntaro Ikegawa, Nobuharu Fujii, Yoshinobu Maeda, Isao Date

    NMC case report journal   9   275 - 280   2022年

     詳細を見る

    記述言語:英語  

    Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there are limited reports on CAR-T cell therapy for PCNSL because of the concern of neurotoxicity. Here, we report a case of relapsed PCNSL treated with anti-CD19 CAR-T cell therapy. A 40-year-old woman presenting with visual disturbance in her left eye was initially diagnosed with bilateral uveitis. Her histological diagnosis was DLBCL, and she was positive for CD19. Although she received chemotherapy including HD-MTX, the tumor relapsed in her right occipital lobe. She underwent remission induction therapy and then anti-CD19 CAR-T cell therapy. Cytokine release syndrome (CRS) grade 2 occurred, but there were no complications of CAR-T cell-related encephalopathy syndrome (CRES). She has achieved complete response for more than 1 year. Anti-CD19 CAR-T cell therapy is a revolutionary immunotherapy for treating relapsed or refractory (R/R) B lineage malignancies. Although there are concerns regarding CRS and CRES in central nervous system lymphoma, the use of anti-CD19 CAR-T cells to treat R/R PCNSL is safe and feasible.

    DOI: 10.2176/jns-nmc.2022-0134

    PubMed

    researchmap

  • Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion. 国際誌

    Kazuhiko Kurozumi, Kentaro Fujii, Kana Washio, Joji Ishida, Yoshihiro Otani, Tamotsu Sudo, Makoto Tahara, Koichi Ichimura, Daisuke Ennishi, Isao Date

    Neuro-oncology advances   4 ( 1 )   vdac094   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/noajnl/vdac094

    Scopus

    PubMed

    researchmap

  • Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study. 国際誌

    Hirokazu Takami, Christopher S Graffeo, Avital Perry, Makoto Ohno, Joji Ishida, Caterina Giannini, Yoshitaka Narita, Yoichi Nakazato, Nobuhito Saito, Ryo Nishikawa, Masao Matsutani, Koichi Ichimura, David J Daniels

    Journal of neuro-oncology   154 ( 1 )   121 - 130   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s11060-021-03810-x

    Scopus

    PubMed

    researchmap

  • Large-vessel vasculitis induced by granulocyte colony-stimulating factor administration after chemotherapy. 国際誌

    Koichiro Yamamoto, Nayu Tamura, Kosuke Oka, Kou Hasegawa, Hideharu Hagiya, Madoka Hokama, Joji Ishida, Fumio Otsuka

    Modern rheumatology case reports   5 ( 2 )   322 - 326   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Granulocyte colony-stimulating factor (G-CSF) is a relatively new drug that is used for recovery of chemotherapy-associated neutropenia. It is known to cause bone pain, headache and fatigue as side-effects; however, large-vessel vasculitis is extremely rare and its relation with G-CSF remains unknown. We describe a 49-year-old woman in whom arteritis developed after chemotherapy and subsequent G-CSF administration. She had experienced pinealoma 3 months ago and received surgery and chemotherapy, leading to neutropenia. After administration of lenograstim at 100 μg/day for 1 week, high fever and neck pain appeared. White blood cell count and serum levels of C-reactive protein and interleukin-6 were increased to 37,930/μL, 23.71 mg/dL, and 241 pg/mL, respectively. Contrast-enhanced computed tomography revealed thickened walls of large vessels including the bilateral common carotid artery (CCA), right brachiocephalic artery, and ascending aorta. Ultrasonography showed wall thickening of the CCA (maximum of intima media thickness: right, 2.9 mm; left, 3.2 mm). As differential diagnoses, infection, chemotherapy, autoimmune diseases, and cancer were considered other than G-CSF. Blood culture tests, lumbar puncture, β-D-glucan tests, and tests for viral antibodies indicated no active infection, and autoantibodies were negative. Empirical antibiotic therapy was ineffective. The score of Naranjo's algorithm to lenograstim was 6, indicating "probable" causality. Considering the clinical course and test results, we made a diagnosis of G-CSF-associated arteritis and commenced glucocorticoid therapy, which drastically improved the symptoms and inflammation. Clinicians should be aware of this uncommon but significant complication of GCS-F administration, for which glucocorticoid treatment can be a useful therapeutic option.

    DOI: 10.1080/24725625.2020.1857022

    PubMed

    researchmap

  • Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets. 国際誌

    Uswa Shahzad, Michael S Taccone, Sachin A Kumar, Hidehiro Okura, Stacey Krumholtz, Joji Ishida, Coco Mine, Kyle Gouveia, Julia Edgar, Christian Smith, Madeline Hayes, Xi Huang, W Brent Derry, Michael D Taylor, James T Rutka

    Neuro-oncology   23 ( 5 )   718 - 731   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/neuonc/noaa306

    Scopus

    PubMed

    researchmap

  • Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration. 国際誌

    Atsuhito Uneda, Kazuhiko Kurozumi, Atsushi Fujimura, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Yoshihiro Otani, Yusuke Tomita, Yasuhiko Hattori, Yuji Matsumoto, Nobushige Tsuboi, Keigo Makino, Shuichiro Hirano, Atsunori Kamiya, Isao Date

    Acta neuropathologica communications   9 ( 1 )   29 - 29   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40478-021-01124-7

    Scopus

    PubMed

    researchmap

  • MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma. 国際誌

    Joji Ishida, Saira Alli, Andrew Bondoc, Brian Golbourn, Nesrin Sabha, Kristina Mikloska, Stacey Krumholtz, Dilakshan Srikanthan, Naohide Fujita, Amanda Luck, Colin Maslink, Christian Smith, Kullervo Hynynen, James Rutka

    Journal of controlled release : official journal of the Controlled Release Society   330   1034 - 1045   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jconrel.2020.11.010

    Scopus

    PubMed

    researchmap

  • Diffuse intrinsic pontine glioma: current insights and future directions. 国際誌

    Dilakshan Srikanthan, Michael S Taccone, Randy Van Ommeren, Joji Ishida, Stacey L Krumholtz, James T Rutka

    Chinese neurosurgical journal   7 ( 1 )   6 - 6   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s41016-020-00218-w

    Scopus

    PubMed

    researchmap

  • Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases.

    Satoru Yabuno, Satoshi Kawauchi, Michiari Umakoshi, Atsuhito Uneda, Kentaro Fujii, Joji Ishida, Yoshihiro Otani, Yasuhiko Hattori, Nobushige Tsuboi, Shohei Kohno, Mai Noujima, Tomohiro Toji, Hiroyuki Yanai, Takao Yasuhara, Isao Date

    NMC case report journal   8 ( 1 )   505 - 511   2021年

     詳細を見る

    記述言語:英語  

    "Diffuse midline glioma (DMG), H3K27M-mutant" was newly classified in the revised World Health Organization (WHO) 2016 classification of central nervous system tumors. Spinal cord DMG, H3K27M-mutant is relatively rare, with poor prognosis, and there are no effective treatment protocols. In this study, we report two cases of spinal cord DMG, H3K27M-mutant treated with bevacizumab. The two patients were women in their 40s who initially presented with sensory impairment. MRI showed spinal intramedullary tumors, and each patient underwent laminectomy/laminoplasty and biopsy of the tumors. Histological examination initially suggested low-grade astrocytoma in case 1 and glioblastoma in case 2. Upon further immunohistochemical examination in case 1 and molecular examination in case 2, however, both cases were diagnosed as DMG, H3K27M-mutant. Case 1 was treated with radiation therapy and temozolomide (TMZ) chemotherapy, which induced a transient improvement of symptoms; 3 months after surgery, however, the patient's symptoms rapidly deteriorated. MRI showed tumor enlargement with edema to the medulla. Triweekly administration of bevacizumab improved her symptoms for the following 12 months. Case 2 was treated with bevacizumab from the beginning because of acute deterioration of breathing. After bevacizumab administration, both cases showed tumor regression on MRI and drastic improvement of symptoms within a few days. Although spinal cord DMG, H3K27M-mutant has an aggressive clinical course and poor prognosis, bevacizumab administration may offer the significant clinical benefit of alleviating edema, which improves patient's capacity for activities of daily life.

    DOI: 10.2176/nmccrj.cr.2021-0033

    PubMed

    researchmap

  • Carotid-anterior cerebral artery (ACA) anastomosis associated with azygos ACA and ophthalmic artery arising from the middle meningeal artery: a case report. 国際誌

    Koichiro Matsuura, Akira Uchino, Naoko Saito, Joji Ishida, Tomonari Suzuki

    Surgical and radiologic anatomy : SRA   42 ( 2 )   211 - 214   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00276-019-02353-1

    Scopus

    PubMed

    researchmap

  • High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.

    Kazuhiko Kurozumi, Yoshiko Nakano, Joji Ishida, Takehiro Tanaka, Masatomo Doi, Junko Hirato, Akihiko Yoshida, Kana Washio, Akira Shimada, Takashi Kohno, Koichi Ichimura, Hiroyuki Yanai, Isao Date

    Brain tumor pathology   36 ( 3 )   121 - 128   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10014-019-00345-y

    Scopus

    PubMed

    researchmap

  • δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion. 国際誌

    Toshihiko Shimizu, Joji Ishida, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Yoshihiro Otani, Tetsuo Oka, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Isao Date

    Molecular cancer therapeutics   18 ( 4 )   812 - 822   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1535-7163.MCT-18-0138

    Scopus

    PubMed

    researchmap

  • Delayed postoperative hyponatremia after endoscopic transsphenoidal surgery for pituitary adenoma. 国際誌

    Yusuke Tomita, Kazuhiko Kurozumi, Kenichi Inagaki, Masahiro Kameda, Joji Ishida, Takao Yasuhara, Tomotsugu Ichikawa, Tomoko Sonoda, Fumio Otsuka, Isao Date

    Acta neurochirurgica   161 ( 4 )   707 - 715   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00701-019-03818-3

    Scopus

    PubMed

    researchmap

  • Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma. 国際誌

    Yoshihiro Otani, Tomotsugu Ichikawa, Atsuhito Uneda, Kazuhiko Kurozumi, Joji Ishida, Isao Date

    World neurosurgery   116   464 - 471   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.wneu.2018.05.036

    Scopus

    PubMed

    researchmap

  • Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. 査読 国際誌

    Y Otani, T Ichikawa, K Kurozumi, S Inoue, J Ishida, T Oka, T Shimizu, Y Tomita, Y Hattori, A Uneda, Y Matsumoto, H Michiue, I Date

    Oncogene   37 ( 6 )   777 - 786   2018年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/onc.2017.373

    Scopus

    PubMed

    researchmap

  • Combination of the tubular retractor and brain spatulas provides an adequate operative field in surgery for deep-seated lesions: Case series and technical note. 国際誌

    Yoshihiro Otani, Kazuhiko Kurozumi, Joji Ishida, Masafumi Hiramatsu, Masahiro Kameda, Tomotsugu Ichikawa, Isao Date

    Surgical neurology international   9 ( 1 )   220 - 220   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.4103/sni.sni_62_18

    Scopus

    PubMed

    researchmap

  • FIBROBLAST GROWTH FACTOR 13 REGULATES GLIOMA CELL INVASION 査読

    Yoshihiro Otani, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Satoshi Inoue, Joji Ishida, Tetsuo Oka, Toshihiko Shimizu, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Hiroyuki Michiue, Isao Date

    NEURO-ONCOLOGY   19   21 - 21   2017年11月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma. 国際誌

    Yoshihiro Otani, Joji Ishida, Kazuhiko Kurozumi, Tetsuo Oka, Toshihiko Shimizu, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Hiroyuki Michiue, Shuta Tomida, Takehiro Matsubara, Tomotsugu Ichikawa, Isao Date

    Scientific reports   7 ( 1 )   7391 - 7391   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-017-07745-0

    Scopus

    PubMed

    researchmap

  • Simultaneous combination of electromagnetic navigation with visual evoked potential in endoscopic transsphenoidal surgery: clinical experience and technical considerations. 国際誌

    Kazuhiko Kurozumi, Masahiro Kameda, Joji Ishida, Isao Date

    Acta neurochirurgica   159 ( 6 )   1043 - 1048   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00701-017-3111-6

    Scopus

    PubMed

    researchmap

  • 診断に苦慮している左前頭葉嚢胞性腫瘍の一例

    黒住 和彦, 石田 穣治, 市川 智継, 大谷 理浩, 清水 俊彦, 冨田 祐介, 服部 靖彦, 田中 健大, 柳井 広之, 伊達 勲

    Brain Tumor Pathology   34 ( Suppl. )   090 - 090   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 診断と治療方針に苦慮した左前頭葉嚢胞性腫瘍の1例

    石田 穣治, 黒住 和彦, 市川 智継, 大谷 理浩, 服部 靖彦, 清水 俊彦, 冨田 祐介, 鷲尾 佳奈, 嶋田 明, 田中 健大, 柳井 広之, 伊達 勲

    小児の脳神経   42 ( 2 )   201 - 201   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • Perioperative Management Center (PERIO) for Neurosurgical Patients.

    Takao Yasuhara, Tomohito Hishikawa, Takashi Agari, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Masahiro Kameda, Aiko Shinko, Joji Ishida, Masafumi Hiramatsu, Motomu Kobayashi, Yoshikazu Matsuoka, Toshihiro Sasaki, Yoshihiko Soga, Reiko Yamanaka, Takako Ashiwa, Akemi Arioka, Yasuko Hashimoto, Ayasa Misaki, Yuriko Ishihara, Machiko Sato, Hiroshi Morimatsu, Isao Date

    Neurologia medico-chirurgica   56 ( 9 )   574 - 9   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Perioperative management is critical for positive neurosurgical outcomes. In order to maintain safe and authentic perioperative management, a perioperative management center (PERIO) was introduced to patients of our Neurosurgery Department beginning in June 2014. PERIO involves a multidisciplinary team consisting of anesthesiologists, dentists/dental hygienists/technicians, nurses, physical therapists, pharmacists, and nutritionists. After neurosurgeons decide on the course of surgery, a preoperative evaluation consisting of blood sampling, electrocardiogram, chest X-ray, and lung function test was performed. The patients then visited the PERIO clinic 7-14 days before surgery. One or two days before surgery, the patients without particular issues enter the hospital and receive a mouth cleaning one day before surgery. After surgery, postoperative support involving eating/swallowing evaluation, rehabilitation, and pain control is provided. The differences in duration from admission to surgery, cancellation of surgery, and postoperative complications between PERIO and non-PERIO groups were examined. Eighty-five patients were enrolled in the PERIO group and 131 patients in the non-PERIO group. The duration from admission to surgery was significantly decreased in the PERIO group (3.6 ± 0.3 days), compared to that in the non-PERIO group (4.7 ± 0.2 days). There was one cancelled surgery in the PERIO group and six in the non-PERIO group. Postoperative complications and the overall hospital stay did not differ between the two groups. The PERIO system decreased the duration from admission to surgery, and it is useful in providing high-quality medical service, although the system should be improved so as not to increase the burden on medical staff.

    DOI: 10.2176/nmc.oa.2016-0085

    PubMed

    researchmap

  • A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy. 国際誌

    Tetsuo Oka, Kazuhiko Kurozumi, Yosuke Shimazu, Tomotsugu Ichikawa, Joji Ishida, Yoshihiro Otani, Toshihiko Shimizu, Yusuke Tomita, Masakiyo Sakaguchi, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Isao Date

    Scientific reports   6   33319 - 33319   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep33319

    Scopus

    PubMed

    researchmap

  • [Cilengitide].

    Kazuhiko Kurozumi, Joji Ishida, Tomotsugu Ichikawa, Isao Date

    Nihon rinsho. Japanese journal of clinical medicine   74 Suppl 7   672 - 676   2016年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • [Molecular targeted drugs in gliomas].

    Kazuhiko Kurozumi, Joji Ishida, Tomotsugu Ichikawa, Isao Date

    Nihon rinsho. Japanese journal of clinical medicine   74 Suppl 7   665 - 671   2016年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • Adhesion molecules and the extracellular matrix as drug targets for glioma.

    Toshihiko Shimizu, Kazuhiko Kurozumi, Joji Ishida, Tomotsugu Ichikawa, Isao Date

    Brain tumor pathology   33 ( 2 )   97 - 106   2016年4月

     詳細を見る

  • Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion. 国際誌

    Hiroyuki Mori, Yao Yao, Brian S Learman, Kazuhiko Kurozumi, Joji Ishida, Sadeesh K Ramakrishnan, Katherine A Overmyer, Xiang Xue, William P Cawthorn, Michael A Reid, Matthew Taylor, Xiaomin Ning, Yatrik M Shah, Ormond A MacDougald

    Scientific reports   6   21520 - 21520   2016年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Changes in cellular oxygen tension play important roles in physiological processes including development and pathological processes such as tumor promotion. The cellular adaptations to sustained hypoxia are mediated by hypoxia-inducible factors (HIFs) to regulate downstream target gene expression. With hypoxia, the stabilized HIF-α and aryl hydrocarbon receptor nuclear translocator (ARNT, also known as HIF-β) heterodimer bind to hypoxia response elements (HREs) and regulate expression of target genes. Here, we report that WNT11 is induced by hypoxia in many cell types, and that transcription of WNT11 is regulated primarily by HIF-1α. We observed induced WNT11 expression in the hypoxic area of allograft tumors. In addition, in mice bearing orthotopic malignant gliomas, inhibition with bevacizumab of vascular endothelial growth factor, which is an important stimulus for angiogenesis, increased nuclear HIF-1α and HIF-2α, and expression of WNT11. Gain- and loss-of-function approaches revealed that WNT11 stimulates proliferation, migration and invasion of cancer-derived cells, and increases activity of matrix metalloproteinase (MMP)-2 and 9. Since tumor hypoxia has been proposed to increase tumor aggressiveness, these data suggest WNT11 as a possible target for cancer therapies, especially for tumors treated with antiangiogenic therapy.

    DOI: 10.1038/srep21520

    PubMed

    researchmap

  • Hybrid Microscopic-Endoscopic Surgery for Craniopharyngioma in Neurosurgical Suite: Technical Notes. 国際誌

    Tomotsugu Ichikawa, Yoshihiro Otani, Joji Ishida, Kentaro Fujii, Kazuhiko Kurozumi, Shigeki Ono, Isao Date

    World neurosurgery   85   340 - 8   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: The best chance of curing craniopharyngioma is achieved by microsurgical total resection; however, its location adjacent to critical structures hinders complete resection without neurologic deterioration. Unrecognized residual tumor within microscopic blind spots might result in tumor recurrences. To improve outcomes, new techniques are necessary to visualize tissue within these blind spots. We examined the success of hybrid microscopic-endoscopic neurosurgery for craniopharyngioma in a neurosurgical suite. METHODS: Four children with craniopharyngiomas underwent microscopic resection. When the neurosurgeon was confident that most of the visible tumor was removed but was suspicious of residual tumor within the blind spot, he or she used an integrated endoscope-holder system to inspect and remove any residual tumor. Two ceiling monitors were mounted side by side in front of the surgeon to display both microscopic and endoscopic views and to view both monitors simultaneously. RESULTS: Surgery was performed in all patients via the frontobasal interhemispheric approach. Residual tumors were observed in the sella (2 patients), on the ventral surface of the chiasm and optic nerve (1 patient), and in the third ventricle (1 patient) and were resected to achieve total resection. Postoperatively, visual function was improved in 2 patients and none exhibited deterioration related to the surgery. CONCLUSIONS: Simultaneous microscopic and endoscopic observation with the use of dual monitors in a neurosurgical suite was ergonomically optimal for the surgeon to perform microsurgical procedures and to avoid traumatizing surrounding vessels or neural tissues. Hybrid microscopic-endoscopic neurosurgery may contribute to safe, less-invasive, and maximal resection to achieve better prognosis in children with craniopharyngioma.

    DOI: 10.1016/j.wneu.2015.08.058

    PubMed

    researchmap

  • Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma.

    Joji Ishida, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Yoshihiro Otani, Manabu Onishi, Kentaro Fujii, Yosuke Shimazu, Tetsuo Oka, Toshihiko Shimizu, Isao Date

    Brain tumor pathology   32 ( 4 )   245 - 52   2015年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Recently, research efforts in identifying prognostic molecular biomarkers for malignant glioma have intensified. Cysteine-rich protein 61 (CCN1) is one of the CCN family of matricellular proteins that promotes cell growth and angiogenesis in cancers through its interaction with several integrins. In this study, we investigated the relationships among CCN1, O(6)-methylguanine-DNA methyltransferase expression, the tumor removal rate, and prognosis in 46 glioblastoma patients treated at the Okayama University Hospital. CCN1 expression was high in 31 (67 %) of these patients. The median progression-free survival (PFS) and overall survival (OS) times of patients with high CCN1 expression was significantly shorter than those of patients with low CCN1 expression (p < 0.005). In a multivariate Cox analysis, CCN1 proved to be an independent prognostic factor for patient survival [PFS, hazard ratio (HR) = 3.53 (1.55-8.01), p = 0.003 and OS, HR = 3.05 (1.35-6.87), p = 0.007]. Moreover, in the 31 patients who underwent gross total resection, the PFS and OS times of those with high CCN1 expression were significantly shorter than those with low CCN1 expression. It was concluded that CCN1 might emerge as a significant prognostic factor regarding the prognosis of glioblastoma patients.

    DOI: 10.1007/s10014-015-0227-3

    PubMed

    researchmap

  • Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma.

    Manabu Onishi, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Satoshi Inoue, Tomoko Maruo, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Koichi Yoshida, Hiroyuki Michiue, E Antonio Chiocca, Isao Date

    Brain tumor pathology   32 ( 3 )   184 - 94   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We have established a pair of animal models (J3T-1 and J3T-2) with different invasive and angiogenic phenotypes, and demonstrated that annexin A2 is expressed at higher levels in J3T-1 than J3T-2 cells. The function of annexin A2 in relation to angiogenesis and invasion was investigated using these models. Stable silencing or overexpression of annexin A2 in J3T-1 and J3T-2 cells (J3T-1shA and J3T-2A cells) was established and used. Thirty human glioblastoma samples were evaluated for expression of annexin A2, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Immunohistochemical and quantitative reverse-transcription polymerase chain reaction analyses revealed higher expression of annexin A2, VEGF and PDGF in J3T-1 and J3T-2A cells. Cultured J3T-1 and J3T-2A cells exhibited higher adhesive ability to endothelial cells. Histopathological analysis of animal brain tumors revealed that J3T-1 and J3T-2A tumors displayed marked angiogenesis and invasion along the neovasculature, whereas J3T-2 and J3T-1shA tumors exhibited diffuse, infiltrative invasion without angiogenesis. Positive expression of annexin A2 was observed in tumor cells surrounding dilated vessels in 25/30 human glioblastoma specimens. Our results reveal that the phenotype of glioma invasion is closely related to angiogenesis. We identify annexin A2 as a factor regulating angiogenesis and invasion of malignant gliomas.

    DOI: 10.1007/s10014-015-0216-6

    PubMed

    researchmap

  • Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma 査読

    Y. Shimazu, K. Kurozumi, T. Ichikawa, K. Fujii, M. Onishi, J. Ishida, T. Oka, M. Watanabe, Y. Nasu, H. Kumon, I. Date

    GENE THERAPY   22 ( 2 )   146 - 154   2015年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/gt.2014.100

    Web of Science

    researchmap

  • Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. 国際誌

    Tomotsugu Ichikawa, Kazuhiko Kurozumi, Hiroyuki Michiue, Joji Ishida, Yoshinobu Maeda, Eisei Kondo, Akihiro Kawasaki, Isao Date

    Clinical neurology and neurosurgery   127   106 - 11   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Although high-dose methotrexate and whole-brain radiation therapy (WBRT) is the current standard for primary central nervous system lymphoma (PCNSL), it has a limited response rate and produces radiation-induced neurotoxicity. We report the effect of a combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) for immunocompetent patients with PCNSL. METHODS: We analyzed 24 patients who had received M-CHOP administered in 28-day cycles with or without WBRT. The response rate to M-CHOP, overall survival (OS), and recurrence-free survival (RFS) were analyzed. RESULTS: Nine patients were treated with M-CHOP plus WBRT and 15 patients were treated with M-CHOP alone. Twenty-one patients achieved a complete response and three patients achieved a partial response to M-CHOP, for a 100% response rate. With a median follow-up of 70 months, the median OS and RFS were 33 and 13 months, respectively. The median OS for patients treated with M-CHOP plus WBRT and M-CHOP alone was 33 and 32 months, respectively. Of the 13 patients whose age was above 65 years, the median OS for the M-CHOP plus WBRT group (two patients) and the M-CHOP alone group (11 patients) was 14 and 32 months, respectively. Toxicities related to M-CHOP were mostly hematologic and generally mild to moderate. Two patients whose age was above 65 years in the M-CHOP plus WBRT group developed neurotoxicity. CONCLUSION: Combined treatment with M-CHOP was well tolerated and produced a high response rate. Deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis, especially in elderly patients.

    DOI: 10.1016/j.clineuro.2014.10.011

    PubMed

    researchmap

  • Integrin inhibitor suppresses bevacizumab-induced glioma invasion. 国際誌

    Joji Ishida, Manabu Onishi, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Kentaro Fujii, Yosuke Shimazu, Tetsuo Oka, Isao Date

    Translational oncology   7 ( 2 )   292 - 302   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Glioblastoma is known to secrete high levels of vascular endothelial growth factor (VEGF), and clinical studies with bevacizumab, a monoclonal antibody to VEGF, have demonstrated convincing therapeutic benefits in glioblastoma patients. However, its induction of invasive proliferation has also been reported. We examined the effects of treatment with cilengitide, an integrin inhibitor, on bevacizumab-induced invasive changes in glioma. U87ΔEGFR cells were stereotactically injected into the brain of nude mice or rats. Five days after tumor implantation, cilengitide and bevacizumab were administered intraperitoneally three times a week. At 18 days after tumor implantation, the brains were removed and observed histopathologically. Next, the bevacizumab and cilengitide combination group was compared to the bevacizumab monotherapy group using microarray analysis. Bevacizumab treatment led to increased cell invasion in spite of decreased angiogenesis. When the rats were treated with a combination of bevacizumab and cilengitide, the depth of tumor invasion was significantly less than with only bevacizumab. Pathway analysis demonstrated the inhibition of invasion-associated genes such as the integrin-mediated cell adhesion pathway in the combination group. This study showed that the combination of bevacizumab with cilengitide exerted its anti-invasive effect. The elucidation of this mechanism might contribute to the treatment of bevacizumab-refractory glioma.

    DOI: 10.1016/j.tranon.2014.02.016

    PubMed

    researchmap

  • Gene expression profiling of the anti-glioma effect of Cilengitide. 国際誌

    Manabu Onishi, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Hiroyuki Michiue, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, E Antonio Chiocca, Balveen Kaur, Isao Date

    SpringerPlus   2 ( 1 )   160 - 160   2013年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cilengitide (EMD121974), an inhibitor of the adhesive function of integrins, demonstrated preclinical efficacy against malignant glioma. It is speculated that cilengitide can inhibit tumor growth, invasion, and angiogenesis. However, the effects of cilengitide on these processes have not been sufficiently examined. In this study, we investigated the anti-glioma effect of cilengitide using DNA microarray analysis. U87ΔEGFR cells (human malignant glioma cell line) were used for this experiment. The cells were harvested after 16 h of cilengitide treatment, and mRNA was extracted. Gene expression and pathway analyses were performed using a DNA microarray (CodeLink™Human Whole Genome Bioarray). The expression of 265 genes was changed with cilengitide treatment. The expression of 214 genes was up-regulated by more than 4-fold and the expression of 51 genes was down-regulated by more than 4-fold compared to the controls. In pathway analysis, "apoptotic cleavage of cellular proteins" and "TNF receptor signaling pathway" were over-represented. Apoptotic-associated genes such as caspase 8 were up-regulated. Gene expression profiling revealed more detailed mechanism of the anti-glioma effect of cilengitide. Genes associated with apoptosis were over-represented following cilengitide treatment.

    DOI: 10.1186/2193-1801-2-160

    PubMed

    researchmap

  • ANALYSIS OF COMBINATION THERAPY OF THE ADENOVIRUS VECTOR CARRYING REIC/Dkk-3 (Ad-REIC) AND THE INTEGRIN ANTAGONIST CILENGITIDE

    Yosuke Shimazu, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Kentaro Fujii, Manabu Onishi, Joji Ishida, Tetsuo Oka, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Isao Date

    NEURO-ONCOLOGY   15   58 - 58   2013年11月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. 国際誌

    K Fujii, K Kurozumi, T Ichikawa, M Onishi, Y Shimazu, J Ishida, E A Chiocca, B Kaur, I Date

    Cancer gene therapy   20 ( 8 )   437 - 44   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Vasculostatin, the fragment of brain-specific angiogenesis inhibitor-1, shows anti-angiogenic activity against malignant gliomas. Previously, a vasculostatin-expressing oncolytic herpes simplex virus-1, Rapid Antiangiogenesis Mediated By Oncolytic virus (RAMBO), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, combination therapy for malignant glioma. In vitro, tube formation was significantly decreased in RAMBO and cilengitide combination treatment compared with RAMBO or cilengitide monotherapy. Moreover, combination treatment induced a synergistic suppressive effect on endothelial cell migration compared with the control virus. RAMBO, combined with cilengitide, induced synergistic cytotoxicity on glioma cells. In the caspase-8 and -9 assays, the relative absorption of U87ΔEGFR cell clusters treated with cilengitide and with RAMBO was significantly higher than that of those treated with control. In addition, the activity of caspase 3/7 was significantly increased with combination therapy. In vivo, there was a significant increase in the survival of mice treated with combination therapy compared with RAMBO or cilengitide monotherapy. These results indicate that cilengitide enhanced vasculostatin-expressing OV therapy for malignant glioma and provide a rationale for designing future clinical trials combining these two agents.

    DOI: 10.1038/cgt.2013.38

    PubMed

    researchmap

  • 内視鏡下経鼻的経蝶形骨洞手術後の遅発性鼻出血に対し塞栓術が有効であった1例

    岡 哲生, 杉生 憲志, 石田 穣治, 菱川 朋人, 小野 成紀, 徳永 浩司, 伊達 勲

    Neurological Surgery   40 ( 1 )   55 - 60   2012年1月

  • [Usefulness of endovascular treatment for delayed massive epistaxis following endoscopic endonasal transsphenoidal surgery: a case report].

    Tetsuo Oka, Kenji Sugiu, Joji Ishida, Tomohito Hishikawa, Shigeki Ono, Koji Tokunaga, Isao Date

    No shinkei geka. Neurological surgery   40 ( 1 )   55 - 60   2012年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We report here a case of massive nasal bleeding from the sphenopalatine artery three weeks after endonasal transsphenoidal surgery. This 66-year-old male suffered from massive nasal bleeding with the status of hypovolemic shock. Under general anesthesia, an emergent angiography revealed an extravasation from the sphenopalatine artery. Trans-arterial embolization using coil and n-butyl-cyanoacrylate (NBCA) was performed following the diagnostic angiography. Complete occlusion of the injured artery was achieved. The patient showed good recovery from general anesthesia. Delayed nasal bleeding after endonasal transsphenoidal surgery is a rare but important complication. The sphenopalatine artery and its branch are located in the hidden inferior lateral corner of the sphenoid sinus and may be injured during enlargement of the sphenoid opening. When massive delayed nasal bleeding follows transsphenoidal surgery and damage of the internal carotid artery has been ruled out, endovascular treatment of the external carotid artery should be considered.

    PubMed

    researchmap

▼全件表示

MISC

  • NF1関連グリオーマにおける腫瘍微小環境の解析

    駿河和城, 大谷理浩, 松本悠司, 石田穣治, 井上陽平, 平野秀一郎, 藤井謙太郎, 柳井広之, 山本英喜, 里見介史, 市村幸一, 平戸純子, 田中將太

    小児の脳神経(Web)   49 ( 2 )   2024年

     詳細を見る

  • 慢性硬膜下血腫治療後の治療抵抗性硬膜下膿瘍に対して保存的加療を行った一例

    金恭平, 安原隆雄, 石田穣治, 春間純, 三宅隼人, 平田雄一, 永瀬喬之, 菅原千明, 佐々田晋, 杉生憲志

    日本脳神経外傷学会プログラム・抄録集   47th   2024年

     詳細を見る

  • Single Cell Multi Omics and Spatial Analysis Reveals Plasmablast Signature Malignant Cells As a Key of Intratumor Heterogeneity in Primary Central Nervous System Lymphoma

    Hiroki Kobayashi, Ryota Chijimatsu, Ryo Mizuta, Kentaro Fujii, Yoshihiro Otani, Joji Ishida, Yusuke Naoi, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Katsuma Tani, Akira Yamamoto, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda, Daisuke Ennishi

    BLOOD   142   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    DOI: 10.1182/blood-2023-174410

    Web of Science

    researchmap

  • がんゲノム診断とバイオインフォマティクス 大規模全ゲノムおよびトランスクリプトーム解析によるGlioblastoma,IDH-wild typeの多様性の解明

    中島 拓真, 舟越 勇介, 畝田 篤仁, 田中 將太, 石田 穣治, 齋藤 竜太, 花谷 亮典, 吉本 幸司, 成田 善孝, 鈴木 啓道

    Brain Tumor Pathology   40 ( Suppl. )   066 - 066   2023年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 前頭蓋底悪性腫瘍に対する開頭経鼻同時手術の検討

    牧原靖一郎, 秋定直樹, 藤本将平, 清水藍子, 村井綾, 牧野琢丸, 檜垣貴哉, 大谷理浩, 石田穣治, 藤井謙太郎, 安原隆雄, 太田智之, 松本洋, 安藤瑞生

    日本頭蓋底外科学会プログラム・抄録集   35th   2023年

     詳細を見る

  • 膠芽腫の表現型転換を規定する分子生物学的機序の解明

    梅田剛志, 大谷理浩, 松本悠司, 松本悠司, 井上陽平, 外間まどか, 水田亮, 井本良二, 駿河和城, 劒持直也, 家護谷泰仁, 平野秀一郎, 石田穣治, 藤井謙太郎, 伊達勲

    日本脳腫瘍学会学術集会プログラム・抄録集   41st   2023年

     詳細を見る

  • 腫瘍由来血管内皮細胞(TDEC)を標的とした抗うつ薬による新規抗血管新生薬創薬

    道上宏之, 道上宏之, 坪井伸成, 坪井伸成, 大谷理浩, 畝田篤仁, 駿河和城, 松本悠司, 石田穣治, 藤井謙太郎, 黒住和彦, 伊達勲

    日本脳腫瘍学会学術集会プログラム・抄録集   41st   2023年

     詳細を見る

  • CTをベースとした日本人小児の標準的な頭蓋形状・頭蓋容積の検討 頭蓋骨縫合早期癒合症の治療に向けて

    冨田 陽介, 石田 穣治, 亀田 雅博, 妹尾 貴矢, 伊達 勲

    小児の脳神経   47 ( 2 )   243 - 243   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 小児脳腫瘍に対する新規治療 がんゲノム医療時代における小児グリオーマ診療について

    石田 穣治, 藤井 謙太郎, 大谷 理浩, 坪井 伸成, 畝田 篤仁, 鷲尾 佳奈, 柳井 広之, 遠西 大輔, 山本 英喜

    小児の脳神経   47 ( 2 )   162 - 162   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 当科におけるLeksell定位脳生検術の有用性と課題

    皮居 巧嗣, 佐々木 達也, 岡崎 洋介, 細本 翔, 畝田 篤仁, 大谷 理浩, 石田 穣治, 藤井 謙太郎, 佐々田 晋, 安原 隆雄, 伊達 勲

    日本定位・機能神経外科学会プログラム・抄録集   61回   139 - 139   2022年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本定位・機能神経外科学会  

    researchmap

  • あすを創る人材育成・働き方改革 定位脳手術の現在・将来の役割とスキル習得 DBS、脳生検、細胞移植、ウイルス・遺伝子療法、SEEG

    佐々木 達也, 細本 翔, 岡崎 洋介, 皮居 巧嗣, 大谷 理浩, 佐々田 晋, 石田 穣治, 藤井 謙太郎, 安原 隆雄, 伊達 勲

    日本定位・機能神経外科学会プログラム・抄録集   61回   66 - 66   2022年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本定位・機能神経外科学会  

    researchmap

  • がんゲノム医療時代における小児グリオーマ診療について

    石田穣治, 藤井謙太郎, 大谷理浩, 坪井伸成, 畝田篤仁, 鷲尾佳奈, 柳井広之, 遠西大輔, 山本英喜

    小児の脳神経(Web)   47 ( 2 )   2022年

     詳細を見る

  • 大孔部減圧術を施行し,症状の改善が得られた脳幹部神経膠腫の一例

    永瀬喬之, 石田穣治, 佐々田晋, 佐々木達也, 大谷理浩, 藪野諭, 藤井謙太郎, 安原隆雄, 伊達勲

    日本脊髄外科学会プログラム・抄録集   37th   2022年

     詳細を見る

  • 橋発生gliomaに対する生検の有用性

    石田穣治, 藤井謙太郎, 大谷理浩, 佐々木達也, 坪井伸成, 牧野圭悟, 平野秀一郎, 劒持直也, 駿河和城, 井本良二, 水田亮, 細本翔, 永瀬喬之, 伊達勲

    日本脳腫瘍の外科学会プログラム・抄録集   27th   2022年

     詳細を見る

  • 診断に難渋したglioneuronal tumor with neuropil-like islandの一例

    坪井 伸成, 島津 洋介, 枝木 久典, 石田 穣治, 藤井 謙太郎, 黒住 和彦, 柳井 広之, 伊達 勲

    Brain Tumor Pathology   38 ( Suppl. )   109 - 109   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 脳腫瘍と微小環境 分化型膠芽腫細胞はYAP/TAZ-TEAD-CCN1経路によってマクロファージ浸潤を促進し、間葉系微小環境を構築する

    畝田 篤仁, 黒住 和彦, 藤村 篤史, 藤井 謙太郎, 石田 穣治, 坪井 伸成, 牧野 圭悟, 平野 秀一郎, 神谷 厚範, 伊達 勲

    Brain Tumor Pathology   38 ( Suppl. )   054 - 054   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • びまん性内在性橋神経膠腫モデルに対するMRガイド下集束超音波を用いた薬剤送達強化 低侵襲を目指した血液脳関門の克服

    石田 穣治, 藤井 謙太郎, 大谷 理浩, 畝田 篤仁, ヒニネン・クレーボ, ルツカ・ジェームス, 伊達 勲

    小児の脳神経   46 ( 2 )   183 - 183   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 腫瘍微小環境における多細胞間のパラクライン相互作用を介した分化型膠芽腫細胞の役割

    畝田篤仁, 畝田篤仁, 黒住和彦, 黒住和彦, 藤村篤史, 藤井謙太郎, 石田穣治, 島津洋介, 大谷理浩, 冨田祐介, 服部靖彦, 松本悠司, 坪井伸成, 牧野圭悟, 平野秀一郎, 神谷厚範, 伊達勲

    日本脳腫瘍学会プログラム・抄録集   38th   2020年

     詳細を見る

  • 微小環境 神経膠腫(2) Bevacizumab治療におけるグリオーマ浸潤関連因子の検索

    黒住 和彦, 石田 穣治, 大谷 理浩, 清水 俊彦, 冨田 祐介, 松本 悠司, 畝田 篤仁, 服部 靖彦, 藤井 謙太郎, 伊達 勲

    Brain Tumor Pathology   36 ( Suppl. )   071 - 071   2019年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • δ-cateninはbevacizumabによるグリオーマ浸潤の調整に関わる

    牧野圭悟, 清水俊彦, 黒住和彦, 石田穣治, 大谷理浩, 大谷理浩, 冨田祐介, 服部靖彦, 畝田篤仁, 松本悠司, 市川智継, 伊達勲

    日本分子脳神経外科学会プログラム・抄録集   20th   2019年

     詳細を見る

  • δ-cateninはbevacizumab誘導性glioma浸潤を調整する

    清水 俊彦, 黒住 和彦, 石田 穣治, 大谷 理浩, 冨田 祐介, 服部 靖彦, 畝田 篤仁, 松本 悠司, 市川 智継, 伊達 勲

    Brain Tumor Pathology   35 ( Suppl. )   185 - 185   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • NTRK遺伝子融合を有する高悪性度glioneuronal tumorの1例

    黒住 和彦, 中野 嘉子, 石田 穣治, 田中 健大, 土居 正知, 平戸 純子, 吉田 朗彦, 市村 幸一, 柳井 広之, 伊達 勲

    Brain Tumor Pathology   35 ( Suppl. )   171 - 171   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 術中運動神経誘発電位モニタリングを駆使した脳腫瘍摘出術

    石田 穣治, 新光 阿以子, 高橋 和也, 深井 秀幸

    姫路赤十字病院誌   42   77 - 78   2018年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:姫路赤十字病院図書学術委員会  

    researchmap

  • CORRELATION BETWEEN PIK3R1MET326ILE MUTATION, CYSTEINE-RICH PROTEIN 61 EXPRESSION AND POOR PROGNOSIS IN GLIOBLASTOMA

    Kentaro Fujii, Yoshihiro Otani, Joji Ishida, Kazuhiko Kurozumi, Tetsuo Oka, Toshihiko Shimizu, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Hiroyuki Michiue, Tomotsugu Ichikawa, Isao Date

    NEURO-ONCOLOGY   19   97 - 97   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • delta-CATENIN REGULATES BEVACIZUMAB-INDUCED GLIOMA INVASION

    Toshihiko Shimizu, Kazuhiko Kurozumi, Joji Ishida, Tetsuo Oka, Yoshihiro Otani, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Tomotsugu Ichikawa, Isao Date

    NEURO-ONCOLOGY   19   23 - 23   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • δ-cateninはbevacizumab誘導性glioma浸潤を調節する

    清水 俊彦, 黒住 和彦, 石田 穣治, 岡 哲生, 大谷 理浩, 冨田 祐介, 服部 靖彦, 市川 智継, 伊達 勲

    Brain Tumor Pathology   34 ( Suppl. )   134 - 134   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • グリオーマのmicrotubule dynamicsを介した浸潤に関与する遺伝子FGF13の機能解析

    大谷 理浩, 市川 智継, 黒住 和彦, 石田 穣治, 岡 哲生, 清水 俊彦, 冨田 祐介, 服部 靖彦, 道上 宏之, 伊達 勲

    Brain Tumor Pathology   34 ( Suppl. )   095 - 095   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 腫瘍溶解ウイルスRAMBOはbevacizumab誘発性グリオーマ浸潤を抑制する

    冨田 祐介, 黒住 和彦, 服部 靖彦, 清水 俊彦, 岡 哲生, 大谷 理浩, 石田 穣治, 市川 智継, Balveen Kaur, 伊達 勲

    Brain Tumor Pathology   34 ( Suppl. )   099 - 099   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • PIK3R1 germline mutationはGBMにおけるCCN1発現および予後と相関する

    大谷 理浩, 黒住 和彦, 石田 穣治, 岡 哲生, 清水 俊彦, 冨田 祐介, 服部 靖彦, 道上 宏之, 市川 智継, 伊達 勲

    Brain Tumor Pathology   34 ( Suppl. )   111 - 111   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 小児midline gliomaの長期治療成績

    黒住 和彦, 亀田 雅博, 石田 穣治, 服部 靖彦, 大谷 理浩, 清水 俊彦, 冨田 祐介, 藤井 謙太郎, 鷲尾 佳奈, 嶋田 明, 伊達 勲

    小児の脳神経   42 ( 2 )   134 - 134   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    J-GLOBAL

    researchmap

  • 動物モデルを用いた悪性グリオーマのangiogenesis-invasion shiftの機序解明

    松本悠司, 市川智継, 大谷理浩, 黒住和彦, 藤井謙太郎, 石田穣治, 清水俊彦, 冨田祐介, 服部靖彦, 畝田篤仁

    日本脳腫瘍学会プログラム・抄録集   35th   2017年

     詳細を見る

  • Bevacizumab治療におけるglioma浸潤規定因子δ-cateninの検討

    清水俊彦, 黒住和彦, 石田穣治, 岡哲生, 大谷理浩, 冨田祐介, 服部靖彦, 畝田篤仁, 松本悠司, 市川智継, 伊達勲

    日本脳腫瘍学会プログラム・抄録集   35th   2017年

     詳細を見る

  • 近未来の小児神経外科 小児脳神経外科手術における磁場式ナビゲーションの有用性(Usefulness of an electromagnetic neuronavigation system for pediatric neurosurgery)

    黒住 和彦, 亀田 雅博, 石田 穣治, 伊達 勲

    小児の脳神経   41 ( 1 )   72 - 72   2016年5月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • Congenital glioblastoma 2例の分子病理学的解析

    大谷 理浩, 市川 智継, 亀田 雅博, 黒住 和彦, 石田 穣治, 岡 哲生, 清水 俊彦, 冨田 祐介, 柳井 広之, 伊達 勲

    Brain Tumor Pathology   33 ( Suppl. )   096 - 096   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 先天性膠芽腫の臨床的・分子生物学的特徴

    市川 智継, 亀田 雅博, 大谷 理浩, 黒住 和彦, 石田 穣治, 嶋田 明, 鷲尾 佳奈, 柳井 広之, 伊達 勲

    小児の脳神経   41 ( 1 )   81 - 81   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    J-GLOBAL

    researchmap

  • 下垂体腺腫に対するハイビジョンシステムと磁場式ナビゲーション併用神経内視鏡手術の現状-腫瘍・正常境界の見極め-

    黒住和彦, 冨田祐介, 稲垣兼一, 亀田雅博, 安原隆雄, 石田穣治, 松本悠司, 市川智継, 大塚文男, 大塚文男, 伊達勲

    日本間脳下垂体腫瘍学会プログラム・抄録集   26th   2016年

     詳細を見る

  • 小児テント上悪性星細胞腫に対する外科的治療を含めた集学的治療

    黒住 和彦, 市川 智継, 石田 穣治, 亀田 雅博, 伊達 勲

    小児の脳神経   40 ( 1 )   113 - 113   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 中枢神経原発リンパ腫に対する寛解導入後の地固め療法:3つのレジメンの比較

    市川智継, 近藤英生, 黒住和彦, 大谷理浩, 石田穣治, 島津洋介, 岡哲生, 清水俊彦, 冨田祐介, 松本悠司, 前田嘉信, 伊達勲

    日本脳腫瘍学会プログラム・抄録集   33rd   2015年

     詳細を見る

  • 浸潤性グリオーマモデルを用いた浸潤能規定遺伝子の同定と機能解析

    大谷理浩, 市川智継, 黒住和彦, 石田穣治, 島津洋介, 岡哲生, 清水俊彦, 冨田祐介, 松本悠司, 伊達勲

    日本脳腫瘍学会プログラム・抄録集   33rd   2015年

     詳細を見る

  • 浸潤性グリオーマモデルにおける血管新生とpericyteに関する病理学的検討

    松本悠司, 市川智継, 大谷理浩, 黒住和彦, 石田穣治, 島津洋介, 岡哲生, 清水俊彦, 冨田祐介, 伊達勲

    日本脳腫瘍学会プログラム・抄録集   33rd   2015年

     詳細を見る

  • THE ANTI ANGIOGENIC AND INVASIVE EFFECTS OF AN INTEGRIN INHIBITOR AGAINST BEVACIZUMAB-INDUCED INVASIVE GLIOMA

    Joji Ishida, Manabu Onishi, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Kentaro Fujii, Yosuke Shimazu, Tetsuo Oka, Yoshihiro Otani, Toshihiko Shimizu, Isao Date

    NEURO-ONCOLOGY   16   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    DOI: 10.1093/neuonc/nou238.14

    Web of Science

    researchmap

  • 小児脳室近傍腫瘍に対する神経内視鏡と画像支援の有用性

    黒住 和彦, 亀田 雅博, 市川 智継, 安原 隆雄, 石田 穣治, 藤井 謙太郎, 伊達 勲

    小児の脳神経   39 ( 1 )   75 - 75   2014年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 小児テント上悪性星細胞腫に対する集学的治療とその効果について

    石田 穣治, 黒住 和彦, 市川 智継, 亀田 雅博, 藤井 謙太郎, 島津 洋介, 岡 哲生, 伊達 勲

    小児の脳神経   39 ( 1 )   64 - 64   2014年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • MULTIMODAL ANTI-GLIOMA MECHANISMS OF CILENGITIDE DEMONSTRATED BY NOVEL INVASIVE GLIOMA MODELS

    Michiari Umakoshi, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Manabu Onishi, Kentaro Fujii, Joji Ishida, Yoshuke Shimazu, Tetsuo Oka, E. Antonio Chiocca, Balveen Kaur, Isao Date

    NEURO-ONCOLOGY   15   10 - 10   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • GENE EXPRESSION PROFILING OF THE ANTI-GLIOMA EFFECT OF CILENGITIDE

    Kazuhiko Kurozumi, Manabu Onishi, Tomotsugu Ichikawa, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, E. Antonio Chiocca, Balveen Kaur, Isao Date

    NEURO-ONCOLOGY   15   4 - 5   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • OMICS ANALYSIS OF THE ANTI-GLIOMA EFFECT BY COMBINATION THERAPY OF VASCULOSTATIN EXPRESSING ONCOLYTIC VIRUS AND CILENGITIDE

    Kentaro Fujii, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Manabu Onishi, Joji Ishida, Yosuke Shimazu, Balveen Kaur, E. Antonio Chiocca, Isao Date

    NEURO-ONCOLOGY   15   140 - 140   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • ANNEXIN A2 REGULATES ANGIOGENESIS AND INVASION PHENOTYPES OF MALIGNANT GLIOMA

    Tomotsugu Ichikawa, Manabu Onishi, Kazuhiko Kurozumi, Tomoko Maruo, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Tetsuo Oka, E. Antonio Chiocca, Isao Date

    NEURO-ONCOLOGY   15   3 - 3   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • NOVEL ANIMAL GLIOMA MODELS THAT SEPARATELY EXHIBIT TWO DIFFERENT INVASIVE AND ANGIOGENIC PHENOTYPES OF HUMAN GLIOBLASTOMAS

    Tetsuo Oka, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Satoshi Inoue, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, E. Antonio Chiocca, Isao Date

    NEURO-ONCOLOGY   15   8 - 8   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF CYSTEINE-RICH PROTEIN 61 IN GLIOBLASTOMA

    Joji Ishida, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Manabu Onishi, Kentaro Fujii, Yosuke Shimazu, Tetsuo Oka, Isao Date

    NEURO-ONCOLOGY   15   142 - 142   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • 小児脳室近傍腫瘍に対する神経内視鏡的アプローチの有用性

    黒住 和彦, 市川 智継, 亀田 雅博, 小野 成紀, 大西 学, 藤井 謙太郎, 石田 穣治, 島津 洋介, 伊達 勲

    小児の脳神経   38 ( 1 )   115 - 115   2013年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 穿通性頭部外傷に対する当科の治療方針

    亀田 雅博, 石田 穣治, 西田 あゆみ, 小野 成紀, 伊達 勲

    神経外傷   35 ( 2 )   125 - 129   2012年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本脳神経外傷学会  

    researchmap

  • THE INTEGRIN ANTAGONIST CILENGITIDE AUGUMENTS ANTI-TUMOR EFFECT OF VASCULOSTATIN-EXPRESSING ONCOLYTIC VIRUS

    Kentaro Fujii, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Manabu Onishi, Yosuke Shimazu, Joji Ishida, E. Antonio Chiocca, Balveen Kaur, Isao Date

    NEURO-ONCOLOGY   14   28 - 28   2012年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • MULTIPLE MECHANISMS OF CILENGITIDE TREATMENT FOR MALIGNANT GLIOMA

    Kazuhiko Kurozumi, Tomotsugu Ichikawa, Manabu Onishi, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Isao Date

    NEURO-ONCOLOGY   14   26 - 26   2012年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF CYR61 IN MALIGNANT ASTROCYTIC GLIOMA

    Joji Ishida, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Manabu Onishi, Kentaro Fujii, Yosuke Shimazu, Isao Date

    NEURO-ONCOLOGY   14   94 - 94   2012年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • BIMODAL ANTI-GLIOMA MECHANISMS OF CILENGITIDE DEMONSTRATED BY NOVEL INVASIVE GLIOMA MODELS

    T. Ichikawa, K. Kurozumi, M. Onishi, J. Ishida, Y. Shimazu, K. Fujii, S. Inoue, E. A. Chiocca, B. Kaur, I. Date

    NEURO-ONCOLOGY   14   50 - 50   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • 穿通性頭部外傷に対する当科の治療方針

    亀田 雅博, 石田 穣治, 西田 あゆみ, 小野 成紀, 伊達 勲

    日本脳神経外傷学会プログラム・抄録集   35回   67 - 67   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本脳神経外傷学会  

    researchmap

  • 急性膵炎を合併し生検にてIgG4関連下垂体炎と診断し得た1例

    越智 可奈子, 大塚 文男, 中村 絵里, 塚本 尚子, 武田 昌也, 稲垣 兼一, 三好 智子, 三村 由香里, 小倉 俊郎, 石田 穣治, 小野 成紀, 伊達 勲, 槇野 博史

    日本内分泌学会雑誌   87 ( 3 )   949 - 949   2011年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内分泌学会  

    J-GLOBAL

    researchmap

  • 顕微鏡手術における神経内視鏡の役割─神経内視鏡と顕微鏡の使い分けの現状分析を中心に─.

    小野成紀, 石田穣治, 安原隆雄, 黒住和彦, 市川智継, 伊達 勲

    脳神経外科ジャーナル   20 ( 10 )   716 - 724   2011年

     詳細を見る

▼全件表示

共同研究・競争的資金等の研究

  • HDAC阻害薬によるtumor ecosystemの打破と、新規併用療法への応用

    研究課題/領域番号:24K12285  2024年04月 - 2027年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    藤井 謙太郎, 平野 秀一郎, 大谷 理浩, 石田 穣治

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 腸脳相関によるサイトカインを中心とした膠芽腫Cancer Stem Cell Theoryの解明

    研究課題/領域番号:24K12244  2024年04月 - 2027年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    平野 秀一郎, 駿河 和城, 藤井 謙太郎, 大谷 理浩, 石田 穣治

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 空間発現解析による脳腫瘍の形態診断と遺伝子診断の統合による悪性化マーカーの検索

    研究課題/領域番号:24K12222  2024年04月 - 2027年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    駿河 和城, 藤井 謙太郎, 大谷 理浩, 石田 穣治

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 小児脳幹神経膠腫に対する血液脳関門の障壁を克服する治療法の開発

    研究課題/領域番号:23K08569  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    石田 穣治, 大谷 理浩

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    researchmap

  • 脳腫瘍の新規術中蛍光診断システムの構築と治療への応用

    研究課題/領域番号:23K27708  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    田中 將太, 北川 陽介, 石田 穣治, 大谷 理浩, 高柳 俊作, 高見 浩数

      詳細を見る

    配分額:18850000円 ( 直接経費:14500000円 、 間接経費:4350000円 )

    researchmap

  • 脳梗塞に対する細胞移植の治療効果を最大化する、電気刺激・リハビリ併用プロトコール

    研究課題/領域番号:22K09285  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    伊達 勲, 道上 宏之, 藤井 謙太郎, 安原 隆雄, 平松 匡文, 菱川 朋人, 春間 純, 田尻 直輝, 佐々木 達也, 佐々田 晋, 石田 穣治

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    researchmap

  • グリオーマにおける免疫微小環境関連germlineバリアントの解析

    研究課題/領域番号:21K09100  2021年04月 - 2024年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    杉生 憲志, 黒住 和彦, 畝田 篤仁, 藤井 謙太郎, 石田 穣治, 大谷 理浩

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    グリオーマは予後不良な脳腫瘍であり, その中で最も悪性度の高いグリオブラストーマの5年生存率はわずか10%である. 近年, 腫瘍細胞でのみ生じるsomatic(体細胞)遺伝子変異の解析が進んでいるが, 患者が生まれながらに持ち, 体内のすべての細胞で生じるgermline(生殖細胞系列)バリアントについては未だ不明な点が多い. 本邦で開発され, ノーベル賞にも輝いた免疫チェックポイント阻害剤をはじめとする様々な免疫療法が実臨床に応用されているが, グリオーマに対しては有効性を示せていない. 免疫療法の有効性を決定する要素の一つとして, 腫瘍の免疫微小環境が注目されているが, 体内の全細胞に存在するgermlineバリアントは, 腫瘍細胞のみならず免疫微小環境にも強い影響を与える可能性がある. しかし, germlineバリアントと, グリオーマの予後や免疫微小環境との関連に着目して解析を行ったという報告はこれまでにほとんどない. 本研究では, TCGAのグリオーマ患者約のゲノム配列データを用いて, PIK3R1 Met326Ile germline変異がグリオーマの発生率, 予後, さらには免疫微小環境に与える影響について解析を行う. PIK3R1 M326Ileのホモ変異型 (PIK3R1 M326Ile Homo MT)は, 予後が悪い傾向はあるが, 3群解析で有意差はつかず(Homo MT vs WT + Hetero MTで比較すると有意差あり), BLACK OR AFRICAN AMERICANで有意に多いことがわかった. また, 人種ごとに解析した場合も, PIK3R1 M326IleのHomo MTは, 予後が悪い傾向はあることがわかった. 人種ごとに健常人とGBMで比較すると, PIK3R1 M326Ile変異は, 疾患発症リスクには関与しないということがわかった. ホモ変異型 (PIK3R1 M326Ile Homo MT)では, MTAPやIFNの変異が多く, PIK3R1 M326Ile変異が免疫微小環境に影響を与える可能性が示唆された.

    researchmap

  • 遺伝子治療製品「Ad-SGE-REIC」の再発悪性神経膠腫対象第I/IIa相試験

    研究課題/領域番号:20lm0203095h0002  2019年04月 - 2021年03月

    国立研究開発法人日本医療研究開発機構  橋渡し研究戦略的推進プログラムシーズC 

    伊達 勲, 黒住和彦, 藤井謙太郎, 石田穣治, 大谷理浩

      詳細を見る

    資金種別:競争的資金

    配分額:22094000円

    Reduced Expression in Immortalized Cells/Dickkopf-3(REIC/Dkk-3)は岡山大学で発見され,様々ながんで発現が低下している“がん抑制遺伝子”であり,前立腺がん,悪性胸膜中皮腫においてERストレスを介してアポトーシスを誘導すると報告されている.また,前立腺がんにおいてはREIC/Dkk-3による免疫反応を介した抗腫瘍効果の報告もある.悪性神経膠腫細胞に関しては,REIC/Dkk-3がWnt/Dkk-3シグナル伝達経路を阻害し,caspaseを活性化することで細胞増殖を抑制することが報告されている.本研究開発の課題は,“再発悪性神経膠腫を対象とした遺伝子治療製品「Ad-SGE-REIC」の第I/IIa相試験”であり,令和2年度の目標は,症例登録を終了し,すべての症例の評価を終えることとする.

    researchmap

▼全件表示